The newly lowered Kidney Disease: Improving Global Outcomes (KDIGO) blood pressure (BP) target systolic BP (SBP) of <120 mm Hg is associated with improved outcomes compared with the 2012 KDIGO BP target, according to a study published online Aug. 4 in the Journal of Internal Medicine.
Cheol Ho Park, M.D., Ph.D., from Yonsei University in Seoul, South Korea, and colleagues examined the association between the 2021 KDIGO BP target and chronic kidney disease (CKD) progression and compared it to the 2012 KDIGO BP target among 1,724 individuals from Korea with CKD. The main exposure was BP status categorized according to the 2012 or 2021 KDIGO guideline.
The researchers found that during the 8,078 person-years of follow-up, composite kidney outcomes occurred in 37.7 percent of participants. The incidence rates were 55, 66.5, and 116.4 per 1,000 person-years for BP controlled within the 2021 and 2012 KDIGO targets and BP above both targets, respectively. In the multivariable cause-specific hazard model, hazard ratios for the composite outcome were 0.76 for BP controlled within the 2021 target and 1.36 for BP above both targets compared with BP controlled within the 2012 target only.
“Caution should be taken in implementing this new target in clinical practice, and further long-term interventional trials are required to clarify the renoprotective effects of lowering SBP to <120 mm Hg," the authors write.
More information:
Cheol Ho Park et al, The 2021 KDIGO blood pressure target and the progression of chronic kidney disease: Findings from KNOW‐CKD, Journal of Internal Medicine (2023). DOI: 10.1111/joim.13701
Journal information:
Journal of Internal Medicine
Source: Read Full Article
